Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brainsway ( (BWAY) ) just unveiled an announcement.
On March 4, 2026, BrainsWay reported landmark clinical data validating its exclusive FDA-cleared SWIFT accelerated Deep TMS protocol for major depressive disorder, which cuts the acute treatment phase from 20 visits to six half days plus four weekly maintenance sessions. Two new peer-reviewed manuscripts in Brain Stimulation show the accelerated regimen delivers non-inferior efficacy to the standard protocol, posting an 87.8% response rate, 78.0% remission rate and a shorter median time to remission of 21 days versus 28 days.
The findings suggest SWIFT could materially change interventional psychiatry delivery by reducing treatment burden by about 70% in the acute phase, potentially improving patient retention and expanding access as demand for non-drug depression therapies grows. Patient-reported outcomes indicated substantial gains in quality of life and functioning, with roughly 60% returning to normal-range functioning, while recent moves by payers to ease administrative hurdles for Deep TMS underscore a favorable reimbursement backdrop that may strengthen BrainsWay’s competitive position and support broader clinical adoption.
The most recent analyst rating on (BWAY) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
The score is driven primarily by improved profitability, strong cash generation, and a low-leverage balance sheet, reinforced by raised guidance and strong Q3 operating momentum. These positives are tempered by a demanding P/E valuation and technically stretched momentum signals that raise near-term pullback risk.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd. is a global medical technology company specializing in advanced, noninvasive neurostimulation treatments for mental health disorders. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform is FDA-cleared for major depressive disorder, obsessive-compulsive disorder and smoking addiction, with additional clinical trials underway across psychiatric, neurological and addiction indications.
Average Trading Volume: 194,922
Technical Sentiment Signal: Buy
Current Market Cap: $461.5M
Find detailed analytics on BWAY stock on TipRanks’ Stock Analysis page.